I have found that business and finance, rather than science, gives a more sober prediction of what's in the pipeline for PD.

In 2007, I jotted down some notes from "Pharmaceutical Business Review":

"The following drugs are expected to do well in the next 10 years:
Novartis's Stalevo
GSK's Requip Modutab
UCB Schwartz's Neupro

"Although cell/gene therapies show great promise, these approaches will not signficantly impact the sale of pharmaceuticals over the period 2007-2016."